MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, INMB had $3,829K increase in cash & cash equivalents over the period. -$23,624K in free cash flow.

Cash Flow Overview

Change in Cash
$3,829K
Free Cash flow
-$23,624K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Net proceeds from sale of common...
    • Impairment of acquired in-proces...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Research and development tax cre...
    • Purchase of fixed assets
    • Others

Cash Flow
2025-12-31
Net loss
-45,933
Stock-based compensation
9,910
Accretion of debt discount
0
Gain on settlement of accounts payable
-626
Depreciation expense
84
Impairment of acquired in-process research and development intangible assets
16,514
Research and development tax credit receivable
3,103
Other tax receivable
29
Prepaid expenses and other current assets
264
Prepaid expenses related party
0
Other assets
516
Accounts payable and accrued liabilities
1,855
Deferred liabilities
-517
Operating lease liability
43
Net cash used in operating activities
-22,582
Purchase of fixed assets
1,042
Net cash used in investing activities
-1,042
Net proceeds from sale of common stock and warrants
27,544
Cash proceeds for amendment of warrants
67
Exercise of warrants for cash
1
Net cash provided by financing activities
27,612
Impact on cash from foreign currency translation
-159
Net increase (decrease) in cash
3,829
Cash at beginning of year
20,922
Cash at end of year
24,751
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromsale of common stock...$27,544K Cash proceeds foramendment of warrants$67K Exercise of warrants forcash$1K Net cash provided byfinancing activities$27,612K Net increase(decrease) in cash$3,829K Canceled cashflow$23,783K Impairment of acquiredin-process research and...$16,514K Stock-based compensation$9,910K Accounts payable andaccrued liabilities$1,855K Depreciation expense$84K Operating lease liability$43K Net cash used inoperating activities-$22,582K Net cash used ininvesting activities-$1,042K Impact on cash fromforeign currency...-$159K Canceled cashflow$28,406K Net loss-$45,933K Purchase of fixed assets$1,042K Research and developmenttax credit...$3,103K Gain on settlement ofaccounts payable-$626K Deferred liabilities-$517K Other assets$516K Prepaid expenses andother current assets$264K Other tax receivable$29K

Inmune Bio, Inc. (INMB)

Inmune Bio, Inc. (INMB)